Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Protocol

REN532: Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

Diseases

Solid Tumor : Wilms tumor

Description

Wilms tumor is the most common tumor of the kidney, and is seen mainly in young children. There are several stages assigned to these tumors. The stage is determined by how large the tumor is, how far it has spread, and if other tissue has become involved in the disease. The stage of the disease determines the treatment that is given to the patient.

Participants in this research study are also enrolled in another research study known as RENBIO. The RENBIO study evaluates the tumor cells, images of the tumor and its location in the body, and tests to determine the genetic make-up of the tumor. The study provides information that can help better predict the outcome of treating the tumor. Treatments available in this research study are based on the staging and the information gathered from the RENBIO study results.

Objectives

To determine if there are things about the tumor cells that might tell us why standard treatment does not get rid of all tumors
To determine if participants with a higher risk of the tumor returning will benefit from additional chemotherapy drugs
To determine if children less than 2 years old with a small tumor that is contained inside one kidney can be cured with surgery alone

Eligibility

Participant is less than or equal to 30 years of age at the time of diagnosis
Participant is able to perform ordinary tasks and daily activities as defined in the study guidelines
Participant has adequate function of the liver and heart

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Rachel Brennan, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Fax: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article